In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of: 

• Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice 
• The multidisciplinary role in ensuring that BRCA testing is completed for eligible patients 
• Barriers to implementing BRCA testing and adjuvant olaparib in clinical practice and methods to overcome them 
• Administration of adjuvant olaparib with other available adjuvant systemic therapies
• Tolerability of single-agent PARP inhibitors 

Presenters:

Banu Arun, MD
Professor, Breast Medical Oncology 
Director, Clinical Cancer Genetics 

University of Texas MD Anderson Cancer Center 

Houston, Texas 

Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology 
Director, PGY2 Oncology Residency Program 

UK HealthCare 

Assistant Adjunct Professor

UK College of Pharmacy 

Lexington, Kentucky

Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP
Nurse Practitioner 
Breast Oncology

Texas Oncology Baylor Sammons Cancer Center 

Dallas, Texas 

Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp. 

Link to full program:
https://bit.ly/42VeUMM